Alnylam Pharmaceuticals Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Alnylam Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Alnylam Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Wednesday, April, 28th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.04. The biopharmaceutical company earned $177.57 million during the quarter, compared to analysts' expectations of $176.93 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 153.49%. During the same period in the previous year, the business posted ($1.62) EPS.
View Alnylam Pharmaceuticals' earnings history.

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALNY shares have increased by 71.4% and is now trading at $174.63.
View which stocks have been most impacted by COVID-19.

Alnylam Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, May, 6th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $760 million-$860 million, compared to the consensus revenue estimate of $824.74 million.

15 equities research analysts have issued 1 year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $91.00 to $235.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $172.07 in the next twelve months. This suggests that the stock has a possible downside of 1.5%.
View analysts' price targets for Alnylam Pharmaceuticals or view top-rated stocks among Wall Street analysts.

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of ALNY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (8.57%), BlackRock Inc. (7.67%), Price T Rowe Associates Inc. MD (4.74%), JPMorgan Chase & Co. (1.85%), Morgan Stanley (1.52%) and RTW Investments LP (1.43%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Maverick Capital Ltd., JPMorgan Chase & Co., Eaton Vance Management, Bridger Management LLC, Janus Henderson Group PLC, State of Wisconsin Investment Board, and Kornitzer Capital Management Inc. KS. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.

ALNY stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., BlackRock Inc., Federated Hermes Inc., The Manufacturers Life Insurance Company, CIBC Private Wealth Group LLC, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., and Morgan Stanley.
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $174.63.

Alnylam Pharmaceuticals has a market capitalization of $20.53 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858,280,000.00 in net income (profit) each year or ($7.46) on an earnings per share basis.

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

Alnylam Pharmaceuticals was founded in 2002.

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]